Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin

Tsunehiro Takahashi, Sadako Akashi-Tanaka, Takashi Fukutomi, Toru Watanabe, Noriyuki Katsumata, Kunihisa Miyakawa, Tadashi Hasegawa, Hitoshi Tsuda

研究成果: Article査読

6 被引用数 (Scopus)

抄録

Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.

本文言語English
ページ(範囲)234-237
ページ数4
ジャーナルBreast Cancer
8
3
DOI
出版ステータスPublished - 2001 8
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 薬理学(医学)

フィンガープリント

「Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル